iCell Gene Therapeutics

Focus: iCell Gene Therapeutics is a Stony Brook, NY-based gene therapy company focused on CAR-T cell therapies for hematologic malignancies and select autoimmune conditions. Founded in 2014, the company is in early-stage clinical development with a pipeline of 17 programs targeting oncology and immunology indications.

Oncology Gene Therapy

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Open Jobs

About iCell Gene Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow iCell Gene Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

18 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CD4 CAR T cells

T Cell Lymphoma in Relapse

Phase 1

CD7 CAR T cells

T-cell Acute Lymphoblastic Leukemia

Phase 1

Help build intelligence for iCell Gene Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to contribute to a robust CAR-T platform with 17 active programs spanning hematologic malignancies, multiple myeloma, and emerging autoimmune indications like SLE
Early-stage company allows hands-on involvement in program selection and clinical strategy with less bureaucracy than established CAR-T players
Dual oncology and immunology focus (including ICG318 in SLE Phase 1/2) positions company at intersection of high-value therapeutic areas

Watch Out For

Pre-revenue biotech with unspecified funding and cash position creates material risk of dilution, slower hiring, or runway constraints despite 10-year operating history
Only 1 active job opening across entire company signals minimal hiring momentum and limited career progression opportunities in near term
All 17 pipeline programs in Phase 1 (with only 1 Phase 1/2 program) means no near-term regulatory catalysts or revenue visibility; 5 trials active with 0 Phase 3 programs

Generated by Claude from iCell Gene Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BCMA-CS1 cCAR T cells

CD4CAR

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT06197672Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

Phase 1

CD20-CD19 cCAR T cells

B Cell Lymphoma

Phase 1

BCMA-CD19 cCAR T cells

Multiple Myeloma in Relapse

Phase 1

CD4CAR

T-cell Lymphoma

Phase 1

Clinical Trials (1)

NCT03829540CD4CAR for CD4+ Leukemia and Lymphoma